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Immune-mediated inner ear disease can be primary, when the autoimmune response is against the inner ear, or secondary. The latter
is characterized by the involvement of the ear in the presence of systemic autoimmune conditions. Sensorineural hearing loss is the
most common audiovestibular symptom associated with systemic autoimmune diseases, although conductive hearing impairment
may also be present. Hearing loss may present in a sudden, slowly, rapidly progressive or fluctuating form, and is mostly bilateral
and asymmetric. Hearing loss shows a good response to corticosteroid therapy that may lead to near-complete hearing restoration.
Vestibular symptoms, tinnitus, and aural fullness can be found in patients with systemic autoimmune diseases; they often mimic
primary inner ear disorders such as Menière’s disease and mainly affect both ears simultaneously. Awareness of inner ear
involvement in systemic autoimmune diseases is essential for the good response shown to appropriate treatment. However, it is
often misdiagnosed due to variable clinical presentation, limited knowledge, sparse evidence, and lack of specific diagnostic tests.
The aim of this review is to analyse available evidence, often only reported in the form of case reports due to the rarity of some of
these conditions, of the different clinical presentations of audiological and vestibular symptoms in systemic autoimmune diseases.
1. Introduction
The inner ear has been considered for a long time an
immune-privileged site, spared from organ-specific autoim-
munity and rarely involved in systemic autoimmune diseases
thanks to the blood-labyrinthine barrier [1]. Lehnhardt [2]
was the first to hypothesize that sudden or rapidly progres-
sive sensorineural hearing loss (SNHL) could be the result
of an autoimmune process against the inner ear. McCabe
[3] showed the success of steroid and cytotoxic treatment in
a cohort of patients with bilateral progressive SNHL, suggest-
ing an autoimmune pathogenesis. Recently, several studies
showed inflammatory cells in the inner ear, describing the
presence of resident cochlear macrophages in animal models
and the recruitment of inflammatory macrophages to the
cochlea [4]. In 2016, O’Malley et al. identified cells with
staining characteristics and morphology consistent with
macrophages/microglia in the human cochlea [4]; the pres-
ence of these cells in patients with autoimmune diseases sug-
gests that they may have an important role in inner ear
pathology due to the increased level of proinflammatory
cytokines and reactive oxygen species (ROS) induced by
microglia [4].
There is growing interest for inner ear involvement in sys-
temic autoimmune diseases [5, 6]; this condition should be
considered in patients with audiovestibular dysfunction pre-
senting a constellation of symptoms consistent with systemic
autoimmunity or with a preexisting diagnosis of autoimmune
disease [7, 8]. Inner ear involvement in systemic autoimmune
diseases should be distinguished from primary autoimmune
inner ear disease, a condition in which the immune response
acts directly against the inner ear [6, 7].
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Inner ear involvement in autoimmune diseases is esti-
mated to account for less than 1% of all cases of acquired
hearing loss [7] and follows gender and demographic charac-
teristics of autoimmune disorders, with higher prevalence in
female patients between their thirties and fifties [5].
A correct identification of inner ear involvement in
patients with systemic autoimmune diseases is essential for
the possibility of near-complete hearing restoration with
appropriate treatment [9]; however, it is often misdiagnosed
due to variable clinical presentation, limited knowledge,
sparse evidence, and lack of specific diagnostic tests.
The aim of this review is to analyse the available evidence
of the different clinical presentations of audiological and
vestibular symptoms in systemic autoimmune diseases,
although this is often only reported in the form of case
reports due to the rarity of some of these conditions.
2. Inner Ear Involvement in
Autoimmune Diseases
2.1. Pathophysiology of Inner Ear Involvement in
Autoimmune Diseases. Pathophysiology of inner ear involve-
ment in systemic autoimmune diseases is still unclear and
may be related to circulating antibodies against a number
of inner ear antigens leading to antibody-dependent cell-
mediated cytotoxicity, the activation of the complement sys-
tem, a direct action of cytotoxic T cells, or immune complex-
mediated damage [5, 7, 8, 10–14].
The immune complex deposition seems to play a central
role in inner ear involvement; it leads to vasculitis of inner ear
vessels that determines atrophy of the stria vascularis and
SNHL. The deposition of immune complexes reduces the
calibre of the auditory arteries with a consequent decrease
in blood flow; blood flow reduction induces an oxygen deficit
that increases the ROS level responsible for damage to hair
cells and spiral ganglion [15–17]. This pathogenic mecha-
nism appears to be the major factor involved in cochlear
and vestibular damage in systemic autoimmune diseases,
especially when affecting the labyrinthine artery, the com-
mon trunk of the inner ear vascularization system [18].
Temporal bone studies clearly explain the mechanism of
damage. The vascular ischemia, underlying vasculitis, ini-
tially determines the atrophy of the stria vascularis and hair
cell death; the progression of the inflammation initiates bone
inflammatory processes such as necrosis or cochlear fibrosis
[8], more evident in the final stages of the disease [19].
2.2. Audiovestibular Symptoms in Systemic Autoimmune
Diseases. Audiovestibular dysfunction in systemic autoim-
mune diseases may have different clinical presentations with
high interindividual variability [20]. Hearing loss is the most
common condition, followed by tinnitus and vertigo [8].
Characteristics of hearing impairment are extremely var-
iable. The hearing loss is typically sensorineural, affecting
mainly high frequencies [8, 9], although low-frequency and
mid-frequency hearing loss are common in cases of vasculitis
[20]. The general pattern of SNHL is rapidly progressive over
a period of weeks to months, with great timing variability
among different systemic diseases [21]; fluctuations in
hearing are common, although the overall course is a
progressive deterioration of auditory function [9]. Hearing
loss is mainly bilateral and asymmetric; however, cases of
unilateral SNHL that manifests in the contralateral ear after
a variable time have been described [21]. In some cases, a
temporary and acute blood flow reduction in the inner ear
may be related with the onset of sudden sensorineural
hearing loss (SSNHL), with complete or partial recovery after
restoration of normal perfusion. SSNHL is common in
patients with inner ear involvement following systemic auto-
immune diseases, and may be the presenting symptom in
some cases [5, 20]. Despite hearing loss being mainly senso-
rineural, autoimmune diseases can also induce a conductive
hearing loss (CHL). In these cases, CHL may follow the effu-
sions of the middle ear and the inflammation of Eustachian
tube mucosa or involvement of the ossicular chain [22–24].
Tinnitus in systemic autoimmune diseases is mainly
found in association to hearing loss. It has been established
that the decrease of peripheral input following hearing loss
can trigger neuroplastic reactions up to the auditory cortex
responsible for the onset of tinnitus. Therefore, it is probable
that peripheral auditory dysfunction could initiate central
changes that eventually lead to tinnitus onset in patients with
autoimmune diseases [25–28].
Vestibular symptoms, such as rotational vertigo or disequi-
librium,may follow temporary occlusion of the labyrinthine or
the anterior vestibular artery [1, 11], and they often mimic
primary inner ear disorders such as Menière’s disease [3, 21].
A list of systemic autoimmune diseases that have been
reported to be associated to audiovestibular symptoms, along
with relevant literature references, is shown in Table 1.
2.2.1. Systemic Lupus Erythematosus. Systemic lupus erythe-
matosus (SLE) is an autoimmune disease with multiorgan
involvement and an incidence higher in women (82%–96%)
than in men (4%–18%) [29].
The audiovestibular symptoms that are present in
patients with SLE may follow antibody/antigen direct reac-
tions, cytotoxic action, or immune complex deposition [15].
Vasculitis following immune complex deposition is the
major cause of cochlear and vestibular damage in SLE
patients. Immune complexes deposit in the auditory artery
reducing the vessel calibre with a consequent decrease in
blood flow and oxygen deficit; this stimulates the release of
ROS that damage the hair cells and the spiral ganglions with
consequent hearing impairment [16].
SNHL is the most common audiovestibular symptom in
SLE, with a prevalence of between 6% and 70% [15]. Hearing
loss may be bilateral or unilateral, slowly progressive, or sud-
den; it mainly affects high frequencies, mimicking the typical
presbycusis pattern, but may also involve low and middle
frequencies [15]. Maciaszczyk et al. [30] and Roverano et al.
[18] described progressive, bilateral SNHL involving high
frequencies. Khalidi et al. [31] reported unilateral SNHL
involving mid and high frequencies (500, 1000, 2000, and
3000Hz) associated with a 16% word discrimination score
as demonstrated by speech audiometry. Sperling et al. [32]
described both bilateral and slowly progressive SNHL and
unilateral SSNHL in patients with SLE.
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Tinnitus is often associated with hearing loss in SLE,
most probably following peripheral deafferentation [33–35].
The vestibular system could be involved in SLE, but ver-
tigo and dizziness have rarely been reported [35, 36]. Balance
disorders as a consequence of SLE have been observed also in
children [37]; however, the incidence of vestibular symptoms
may be underestimated due to their slowly progressive onset
and consequent compensation by the somatosensory system
and vision.
2.2.2. Cogan’s Syndrome. Cogan’s syndrome (CS), first
described in 1934, is a rare autoimmune disorder character-
ized by ocular and audiovestibular symptoms [39]. CS
develops in young adults, mostly during their first three
decades of life [40, 41]. The origin of CS is still unclear. Anti-
bodies against Cogan peptide have been found in serum of
patients with CS. Also, this peptide antigen shares sequence
homology with CD148 and connexin 26, both involved in
congenital deafness [42].
CS includes a large spectrum of clinical manifestations.
Haynes et al. [43] defined two types of CS, a typical and an
atypical variant. Typical CS is defined by ocular symptoms,
classically presenting as nonsyphilitic interstitial keratitis
(IK), audiovestibular symptoms similar to those of Menière’s
disease (recurrent episodes of hearing loss, tinnitus, and
vertigo), and an interval between the onsets of ocular and
audiovestibular manifestations of less than 2 years. Atypical
CS is characterized by different inflammatory ocular mani-
festations, with or without IK; audiovestibular symptoms
(usually progressive hearing loss); and, most important, a
delay of more than 2 years between the onset of ocular and
audiovestibular manifestations. In many cases, it is difficult
to differentiate between the two types of CS because some
patients do not present IK at the onset of the disease or, alter-
natively, they develop this condition during the following
years. Systemic manifestations are much more frequent in
atypical CS and can be used in the differential diagnosis
between the two types [41].
Inner ear involvement in CS has been reported with a
prevalence of between 31% and 45% [40–44]. The most com-
mon audiovestibular manifestations in CS are hearing loss,
vertigo, tinnitus, ataxia, and oscillopsia [41]. These symp-
toms can appear at any time during the course of the disease
[44]. Hearing loss may be both unilateral and bilateral, often
presenting as SSNHL with fluctuations or progressive wors-
ening over time. Progression to complete bilateral hearing
Table 1: Systemic autoimmune diseases associated to audiovestibular symptoms.
Autoimmune disease Prevalence of audiovestibular involvement Classification Literature reference
Systemic lupus erythematosus 6–70%
Systemic autoimmune
rheumatic disorders
[15, 16, 18]; [29–37]; [38]
Cogan syndrome 31–45% Systemic vasculitis [39–44]; [45]
Sarcoidosis 5–96% Systemic granulomatous diseases [46–50]; [51]
Rheumatoid arthritis 25–72%
Systemic autoimmune rheumatic
disorders
[24]; [52–54]
Antiphospholipid syndrome Case reports only
Autoimmune hypercoagulable
condition
[55–60]
Polyarteritis nodosa Case reports only Systemic vasculitis [61–70]; [71]
Behcet’s disease 12–80% Systemic vasculitis [72–77]; [45]
Takayasu’s arteritis Case reports only Systemic vasculitis [78–85]; [79]; [86]
Relapsing polychondritis 40–54%
Autoimmune connective
tissue disorder
[23]; [87–92]; [93]
Wegener’s granulomatosis 8–65% Systemic vasculitis [94–97]
Susac’s syndrome Case reports only Systemic vasculitis [98–102]; [103]
Sjögren’s syndrome 22–46%
Systemic autoimmune
rheumatic disorders
[22]; [104–109]; [110]
Myasthenia gravis 22–34%
Autoimmune condition affecting
neuromuscular junction
[111–119]; [120]
Multiple sclerosis 1–28%
Autoimmune inflammatory
demyelinating disease
[4, 15]; [121–129]; [130]
Hashimoto thyroiditis Case reports only Autoimmune thyroid disease [131]
Mixed cryoglobulinemia 22% Systemic vasculitis [132]
Giant cell arteritis 7–100% Systemic vasculitis [133–135]
Vogt-Koyanagi-Harada’s disease 48–62% Systemic granulomatous diseases [136]
Ulcerative colitis 2–5%
Autoimmune inflammatory
bowel disease
[137, 138]
Summary of systemic autoimmune diseases that have been reported to be associated to audiovestibular symptoms, along with reported prevalence of
audiovestibular involvement, classification, and relevant references.
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loss has been reported in almost 50% of patients during the
follow-up period, whereas permanent hearing loss in one
ear was observed in 20% of patients [44].
Tinnitus usually follows auditory deafferentation [41].
Abnormal vestibular function is found in 90% of patients
with CS; at least 20% of the patients present spontaneous or
gaze-induced nystagmus. Rarely, patients show clinical
symptoms of vestibulopathy that last for days or weeks from
the time of onset without spontaneous resolution that fre-
quently results to hospitalization [44].
2.2.3. Sarcoidosis. Sarcoidosis is an inflammatory multisys-
tem disease with unknown origin. CNS involvement is
reported in about 5–7% of patients with systemic sarcoidosis,
called neurosarcoidosis (NS) [46].
A cranial nerve neuropathy affecting the facial and
optic nerves is a common finding in up to 80% of NS
patients [46, 47].
Audiovestibular involvement is common in sarcoidosis.
In a review of 50 patients with NS [48], a high incidence of
audiovestibular manifestations was noted. Hearing loss was
present in 49/50, unilateral in 25% and bilateral in 75% of
the patients. Tinnitus was reported in 30 patients (61%),
and vestibular impairment was recorded in 32/50 (64%)
including vertigo, dizziness, and benign paroxysmal posi-
tional vertigo. A complete vestibular function testing was
performed in 24 patients and found abnormalities in 23
(96%). Of those, six (25%) had unilateral alterations, 16
(67%) had bilateral alterations, and one (8%) had a nonloca-
lizing dysfunction. In another review, Babin [49] reported
SNHL in approximately 90% of reported cases, characterized
by sudden or rapidly progressive onset, and vestibular symp-
toms with abnormal vestibular functioning tests in a similar
percentage of cases. In almost 50% of the cases, at least partial
hearing recovery was achieved after high-dose systemic
steroid administration, while balance disorders recovered
either spontaneously or after treatment [49].
A recent study [50] reported two new cases of SSNHL
due to probable NS, each having a quite different clinical
course. In one case, unilateral SSNHL and facial palsy were
the presenting symptoms of NS, while in the second, unilat-
eral SSNHL occurred despite ongoing immunosuppressive
treatment for NS.
2.2.4. Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a
chronic, inflammatory disease affecting nearly 0.6% of the
general population [52]. Principal symptoms referred by
patients are articular and periarticular, although RA can
involve other organs including the heart, lung, skin, and
eye [52].
Several events can lead to audiovestibular alterations dur-
ing the course of RA; thus, a wide variation in the prevalence
of different types of hearing impairment in RA patients may
be found [53]. SNHL is the most common type of hearing
impairment in RA patients ranging from 25% to 72% [53].
Conductive hearing loss and mixed hearing loss have also
been reported, although less frequently [53].
A prospective case-control study [24] compared hearing
disturbances in patients with RA with a control group. In
60% of the RA patients, SNHL was observed and the differ-
ence was statistically significant at 500Hz, 1 kHz, and 2 kHz
in both ears. CHL was reported in 17.1% of the RA patients
compared to 5.7% of patients in the control group, with a
statistically significant difference.
Pathogenesis of CHL in RA is still poorly understood;
several hypotheses have been proposed. A laxity of the mid-
dle ear transducer mechanism [54] was proposed although
other authors [24] suggested increased stiffness of the ossicu-
lar system.
2.2.5. Antiphospholipid Syndrome. The antiphospholipid
syndrome (APS) is an acquired disorder characterized by
the presence of antiphospholipid antibodies such as anticar-
diolipin (aCL) and lupus anticoagulant (LAC) antibodies
causing hypercoagulability. The characteristic triad of the
disease is the association of specific antibodies, arterial or
venous thrombosis, and/or pregnancy morbidity and mortal-
ity [55]. APS is associated with microthrombosis, causing
cutaneous manifestations like purpuric eruptions, livedo reti-
cularis, and skin ulcerations. The involvement of the retina
may cause amaurosis fugax [56].
The involvement of the inner ear has been reported in
APS and may be related to antibodies targeting the small
vessels of the labyrinthine circulation. Endothelial cells
within the cochlear circulation might be activated by anti-
phospholipid antibodies directly or by inducing the forma-
tion of free radicals that, secondarily, damage the
endothelium. These upregulated endothelial cells would ini-
tiate local microthrombus formation and subsequent ische-
mia to the target organ [57].
The association of aCL or LAC antibodies and SNHL was
firstly reported by Naarendorp and Spiera [56] in six patients
with SLE or a lupus-like syndrome. Toubi et al. [58] studied
sudden and progressive SNHL in 30 patients showing that
in the control group, no one had aCL antibodies, whereas
27% of the patient group had aCL antibodies in low to mod-
erate concentration. In a subsequent study, Toubi et al. [59]
reported that 31% of patients with idiopathic SSNHL were
positive for aCL, compared with only 6% of matched control
subjects. A prospective study [60] had 168 patients with pro-
gressive SNHL who underwent a screening panel of blood
tests for autoimmune disease including aCL antibodies,
anti-B2 glycoprotein, and LAC. In this population, forty-
two patients (25%) had at least one elevated antiphospholipid
antibody marker and twenty patients had two or more posi-
tive test results, suggesting that antiphospholipid antibodies
could be involved in the pathogenesis of some forms of inner
ear dysfunction, related to a microthrombus formation in the
labyrinthine vasculature.
2.2.6. Polyarteritis Nodosa. Polyarteritis nodosa (PAN) is a
systemic necrotizing vasculitis that mainly affects medium-
sized arteries, although small arteries may also be involved
[61]. The incidence of PAN ranges from 0 to 1.6 cases per
million, and the prevalence of this disease is approximately
31 cases per million [62]. PAN affects men more frequently
than women and occurs in all ethnic groups; the average
age at onset is approximately 50 years [63].
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The pathogenesis of idiopathic PAN remains enigmatic,
although the clinical response to immunosuppressive ther-
apy suggests that immunological mechanisms play an active
pathogenic role. As in other forms of vasculitis, the presence
of impaired endothelial function could reflect direct endo-
thelial cell activation and damage resulting from primary
inflammatory vasculitis or proinflammatory cytokines or
antibodies [62].
Clinical manifestations of PAN include nonspecific
constitutional manifestations, such as sickness, weight loss,
fever, arthralgia, and myalgia. Dysfunction or damage of tar-
get organs may produce specific symptoms, often caused by
occlusion or rupture of inflamed arteries. The most fre-
quently involved territories are the skin and peripheral
nervous system [62].
SNHL is often reported in PAN [64–66] and, in rare
instances, may occur as the presenting symptom of the dis-
ease [67, 68]. Hearing loss is typically bilateral and symmet-
rical, with sudden onset [67, 69] or a rapidly progressive
course [65, 70]. Alterations found in auditory brainstem
responses (ABR) suggest an inner ear involvement, and the
involvement of low frequencies may resemble those found
in endolymphatic hydrops [69]. Tinnitus, vertigo, and occa-
sional nausea and vomiting may also be found in patients
with PAN [67].
2.2.7. Behcet’s Disease. Behcet’s disease (BD) is a chronic sys-
temic relapsing syndrome affecting young adults and charac-
terized by the presence of recurrent oral and genital ulcers,
ocular inflammation, and skin lesions caused by a vasculitis
involving small vessels [72].
Hearing loss is a common compliant in BD, it is mainly
bilateral and predominantly affects high frequencies; several
studies have reported SNHL following cochlear impairment
ranging from 12% to 80% in BD patients [72, 73]. No rela-
tionship has been found between age or disease duration
and inner ear involvement [73, 74]. A recent survey [75] of
65 BD patients reported that audiovestibular complaints
were found in 47% of patients. The most common symptoms
were tinnitus (11%), hearing loss (10%), and vertigo (8%); a
case of unilateral SSNHL was also reported.
Nearly half of BD patients report orthostatic disequilib-
rium [72]. Studies of the vestibular function [73, 74] showed
that BD mainly causes peripheral lesion rather than damage
to the central vestibular tracts, although another study [76]
showed a higher prevalence of central vestibular syndrome
in BD patients. Magnetic resonance studies did not show
any degenerative conditions of basal ganglia and brainstem
atrophies in BD patients with abnormal vestibular function
tests [75, 76]. Neural involvement in BD (neuro-Behcet)
may appear with dizziness or vertigo as initial symptoms,
mimicking a vestibular neuritis [77].
2.2.8. Takayasu’s Arteritis. Takayasu’s arteritis (TA), also
known as aortitis syndrome, is a vasculitis that mainly affects
large elastic arteries with symptoms caused by organ ische-
mia, aneurysm formation, and inflammation. TA is more
prevalent in women of reproductive age, and clinical features
usually reflect limb or organ ischemia that follow gradual
stenosis of the involved arteries [78, 79].
The aetiology of hearing impairment in TA remains
unknown [79]; it has been hypothesized that hearing loss
follows the elevation of serum immune complexes that
deposits in the inner ear or reversible circulatory distur-
bances with hypercoagulability in response to arterial disease
[80]. Although TA involves medium and large calibre arter-
ies, Noel et al. reported that the occlusion of small retinal
vessels is a possible microcirculatory complication in TA;
common immunopathology mechanisms with hearing loss
could be hypothesized [81]. Moreover, Maruyoshi et al. spec-
ulated that hearing loss in TA could have a vascular back-
ground based on reversible circulatory disturbances due to
vasculitis and/or some autoimmune pathogenesis in the
inner ear, involving especially hair cells [80].
Only a few cases in the literature reported an association
of TA with SNHL [82–84]. Hearing loss is often progressive,
although it can be stable or fluctuating; is usually bilateral
and asymmetric; develops over several weeks to months;
and mainly involves high frequencies. SNHL may also pres-
ent as a SSNHL. A good response to corticosteroid therapy
has been reported for SNHL in TA, although it may also
persist despite therapy [80]. Recently, Ralli et al. described a
case of a 36-year-old woman with TA who had two episodes
of SSNHL involving one ear at a time with an 11-month
delay between each episode of treatment with hyperbaric
oxygen therapy associated to corticosteroids, with significant
improvements in both ears [85, 86].
2.2.9. Relapsing Polychondritis. Relapsing polychondritis
(RP) is a rare connective tissue disorder affecting organs con-
taining collagen, such as the eye, cartilage tissue, and skin.
The diagnosis is based on clinical features and no specific test
for this disease is available; thus, definitive diagnosis takes a
long time, and often, the prognosis is poor [87]. Recurrent
bouts of inflammation may lead to a permanent destruction
of involved structures such as cartilage of the ears, nose,
larynx, tracheobronchial tree, and cardiovascular system
[88]. McAdam et al. [89] proposed diagnostic criteria for
RP when three or more of the six clinical features are present:
recurrent chondritis of both auricles; nonerosive, seronega-
tive inflammatory polyarthritis; chondritis of the nasal carti-
lages; ocular inflammation (conjunctivitis, keratitis, scleritis,
and uveitis); respiratory tract chondritis affecting laryngeal
and tracheal cartilages; and cochlear and/or vestibular dys-
function (SNHL, tinnitus, and vertigo).
Auricular chondritis is a quite specific sign of RP. It is
present in 20% of patients at the onset of the disease and in
90% during the course of the disease [90]. One or both ears
can be affected. The ear concha is swollen, red, or less often
purplish, hot, and painful even at the slightest contact. The
ear lobe, which does not contain the cartilage, is spared.
Audiovestibular impairment is reported in 40–54% of all
patients with RP [91]. These changes can represent the initial
symptoms heralding the outbreak of the disease or appear
after the onset of other symptoms. Typical manifestations
can be bilateral or unilateral, are usually of sudden onset,
and appear as perceptive deafness or tinnitus combined with
5Journal of Immunology Research
or without vertigo and nausea [89]. CHL can be a result of a
serous otitis following chondritis of the eustachian tube [23].
Further, the SNHL in RP patients has been suggested to be
the result of inflammation of the internal auditory artery or
its cochlear branch [92] or due to autoantibodies against
the cochlea and vestibular organ [91]. This could explain
the near-complete hearing recovery in patients after treat-
ment with corticosteroids.
2.2.10. Wegener’s Granulomatosis. Wegener’s granulomato-
sis (WG) is an autoimmune disease of unknown aetiology
characterized by necrotizing granulomatous inflammation
of the respiratory tract, necrotizing glomerulonephritis, and
systemic vasculitis that affects predominantly small vessels.
Although the pulmonary, nasal, and renal manifesta-
tions of WG are well described, hearing symptoms are
less appreciated. Studies available in the literature report
a prevalence of audiovestibular symptoms in 8% to 65%
of patients with WG, mainly auditory symptoms with
SNHL [94, 95] or CHL in cases of WG involving the
middle ear [96]. Audiometric patterns of WG have been
described as typically flat, although sometimes additional
high frequency losses may coexist and differential diagno-
sis with noise exposure or age-related hearing loss may
be difficult [96]. Hearing impairment may also present
as SSNHL; Bakthavachalam et al. [97] identified that hearing
loss was present in 56% of patients suffering from WG
and SSNHL was the most common form, occurring in
47% of cases.
Hearing loss may also be a presenting symptom of WG.
SNHL in WG is believed to be largely irreversible, therefore
potentially adding to the patient’s cumulative disability [96].
SNHL evaluation and monitoring are therefore recom-
mended for appropriate patient management and could
suggest a worsening of disease that may address to a specific
treatment like cyclophosphamide rather than either metho-
trexate or azathioprine [94, 95].
2.2.11. Susac’s Syndrome. Susac’s syndrome (SS) is a rare
immune disease characterized by encephalopathy, branch
retinal artery occlusion, and SNHL [98]. SS has a higher
prevalence in females, with a male: female ratio of 1 : 3.5 [99].
The pathophysiology of SS is not entirely clear. Antien-
dothelial cell antibodies (AECAs) in SS have been recently
documented [99]. Potential targeted antigens suggested in
studies focusing on AECAs include cytoskeletal proteins
(β-actin, α-tubulin, and vimentin), glycolytic enzymes
(glucose-3-phosphate-dehydrogenase and α-enolase), and
the prolyl-4-hydroxylase β subunit, a member of the
disulfide isomerase family [100].
Clinical manifestations of SS are thought to be caused by
autoimmune-mediated occlusions of microvessels in the
brain, retina, and inner ear that lead to a characteristic clin-
ical trial of central nervous system (CNS) dysfunction [101].
At clinical onset, the most common manifestations are CNS
symptoms, observed in two-thirds of patients, followed by
visual symptoms and hearing disturbances. Unfortunately,
only a small number of patients (around 13%) show the
characteristic symptoms of SS at disease onset; thus, defini-
tive diagnosis is often delayed [101].
Hearing loss can be a dramatic and severely debilitating
feature of SS; it may be mild and insidious or may be fluctu-
ating, mimicking Menière’s disease [102]. A loss of low or
middle frequencies is typical, suggesting a vulnerability of
the cochlear apex to microinfarction; loss of high frequencies
can also occur [99]. Hearing loss often occurs overnight and
may affect both ears. Dörr et al. refer to this clinical behav-
iour as the “bang-bang hearing loss” [101]. Severe hearing
loss is often accompanied by vertigo and a roaring tinnitus;
the occlusion of cochlear and vestibular arterioles may be
the cause of these symptoms [99]. In these patients that often
develop severe/profound SNHL and can no longer benefit
from hearing aid amplification, cochlear implantation is a
valid therapeutic option.
2.2.12. Sjögren’s Syndrome. Primary Sjögren’s syndrome
(pSS) is a chronic autoimmune disease characterized by
xerostomia and xerophthalmia due to lymphocyte infiltra-
tion of both salivary and lacrimal glands. It may also occur
as a systemic disease involving the kidneys, lungs, liver,
vessels, and lymph nodes. pSS mainly affects women in the
fourth-fifth decade of life, and presenting symptoms are
often oral and ocular [104]. In this context, autoantibodies
to cardiolipin and M3 muscarinic receptors (mAchRs) in
the serum of pSS patients are suspected to play a pathogenic
role in the onset of progressive hearing loss and neurological
complications [104].
Audiovestibular involvement in patients with pSS has
been reported in the literature with a prevalence ranging
from 22% to 46%. Boki et al. [105] reported in a pSS patient
the presence of SNHL affecting preferentially high frequen-
cies. Tumiati et al. [106] reported SNHL in 46% (14/30) of
patients with pSS. Ziavra et al. [107] diagnosed SNHL in
22.5% (9/40) of pSS patients. Hearing loss as presenting com-
plaint in pSS is quite uncommon and only limited to case
reports [22]; SSNHL was recently reported in a 62-year-old
female treated with high-dose methylprednisolone (250mg)
infusion for 5 days with successful hearing restoration [108].
The high prevalence of cranial neuropathies is a known
condition in pSS, mainly with trigeminal and facial nerve
involvement [109].
Although pSS patients tend to have a higher prevalence
of SNHL compared to the general population, no evidence
of damage to the central auditory pathways was reported
[106]. However, the prevalence of audiovestibular symptoms
in pSS might be underestimated, suggesting that their associ-
ation with pSS was not previously made because it had not
been actively sought [106].
2.2.13. Myasthenia Gravis. Myasthenia gravis (MG) is the
most common autoimmune disorder affecting the neuro-
muscular junction, characterized by muscle weakness and
fatigue [111]. Weakness, the typical clinical symptom of
MG, affects facial, ocular, bulbar, respiratory, or limbmuscles
and worsens after muscular activity [112].
In healthy subjects, acetylcholine (ACh), the primary
neurotransmitter of the efferent auditory system, has been
6 Journal of Immunology Research
found to enhance the electromotility of outer hair cells
(OHC) binding to acetylcholine receptors (AChRs), which
are localized on the postsynaptic membrane of OHC [113].
In patients with MG, autoantibodies against AChRs were
reported to bind with AChRs on OHCs, inducing a progres-
sive loss of AChRs that decreases OHC electromotility [114].
This cascade of events induces apoptosis in all three rows of
OHCs, evolving into a clinically evident SNHL in rare
cases [115]. The efferent auditory system has been investi-
gated using contralateral acoustic stimulation (CAS) [116].
CAS produces physiological suppression of otoacoustic
emissions [117] protecting the hair cells from noise of
moderate to high intensity [118]. A reduced CAS effect has
been reported in patients with MG compared to control
subjects, suggesting a possible role of the progressive
reduction of beta subunits of nicotinic AChRs associated to
the destruction of the basal membrane and OHCs due to
prolonged exposure to autoantibodies [114, 116].
At MG onset, patients do not refer hearing loss and pure
tone audiometry (PTA) is often within normal range. A spe-
cific test studying, the activity of the OHC, otoacoustic emis-
sions (OAE), may show some abnormalities, as OAE have
been found to exhibit greater sensitivity to incipient cochlear
damage compared to PTA, particularly for high frequencies
[115, 119]. A study on 16 MG patients reported a clinical
hearing loss in 30% of the patients, while 100% of the
patients exhibited abnormal distortion product otoacoustic
emissions (DPOAEs) and transient evoked otoacoustic
emissions (TEOAEs) [114]. Therefore, OAE should always
be performed in MG patients because they can early detect
the MG-related effects on the ACh-innervated auditory
system [111].
Additional audiological symptoms, such as tinnitus,
should be always considered and investigated although
seldom reported [27].
Vertigo, also reported in patients with MG, seems to be
more related to musculoskeletal alterations rather than to
vestibular impairment [112].
2.2.14. Multiple Sclerosis.Multiple sclerosis (MS) is tradition-
ally considered an autoimmune inflammatory demyelinating
disease of the central nervous system (CNS). The autoim-
mune pathogenesis of MS is still debated; recently, it has been
hypothesized that it may be a homogeneous degenerative
process analogous to primary neurodegenerative diseases
[121]. As an exacerbating and remitting immune-mediated
disorder of interfascicular oligodendrocyte-produced myelin,
MS can impair acutely and transiently any CNS neural
system, including the auditory pathways [122].
The evidence of a clear presence of macrophages in the
human temporal bone of patients affected by autoimmune
diseases [15] support the hypothesis that in MS, the autoim-
munity mechanisms also affect the structures of the inner ear;
hair cells and auditory and vestibular spiral ganglion neurons
may be subject to the attack of lymphocytes, and their dam-
age may present with SNHL and vertigo. The microglia, a cell
population that belongs to the macrophage family and that is
normally represented in the brain, has been shown to be
active in aggressive forms of MS (phenotype M1). Temporal
bone studies could suggest that microglia can migrate to the
internal auditory canal and to the cochlea [4]. M1 microglia
can demyelinate cochlear and vestibular structures causing
SSNHL or vertigo; such episodes may be temporary due to
the relapsing-remitting phases of MS that activates and inac-
tivates the M1 microglia.
In the literature, several reports showed MS-related hear-
ing deficits. Hearing loss may occur when MS involves both
the peripheral and the brainstem auditory pathways [123];
however, in some case, MS lesions involving the auditory
pathways may not determine a clinically evident hearing
impairment [124]. In rare cases, SSNHLmay be the only pre-
senting symptom of MS and may appear early in the course
of the disease with good prognosis and little or no residual
hearing deficit [125].
MS patients typically report a difficulty in speech percep-
tion, especially in noise [126]. This alteration is due to an
abnormal auditory processing, such as problems with dich-
otic listening tasks and auditory temporal processing [126].
Performance of chronic MS subjects in speech reception
threshold (SRT) is normal in the standard clinical level
(70 dB above the SRT); however, when lower levels are
used, performance significantly decreases compared to age-
matched controls suggesting a deficit in cognitive processing,
such as attention and auditory discrimination, which is
especially required in binaural integration of sound [127].
Furthermore, studies have shown that 40% to 55% of
individuals with MS have at least an episode of dysarthria
or speech alteration characterized by slowness, slurring, or
difficulties in production or comprehension [127].
Disequilibrium in MS is often related to internuclear
ophthalmoplegia, and multiple nystagmus constitutes the
most typical vestibular signs of MS, although peripheral
equilibrium may coexist [128]. Multidirectional nystagmus
without latency may be an atypical central sign, and differ-
ential diagnosis with peripheral disorder, such as benign par-
oxysmal positional vertigo, can be more difficult, although
adaptation and fatigue of nystagmus play a central role in
differential diagnosis. When the clinical findings are not
clear and ex-adjuvantibus criteria cannot be adopted,
vestibular-evoked myogenic potential (VEMP) may be pro-
posed for the differential diagnosis of positional vertigo in
association with careful clinical history and otoneurologic
examination [128].
Audiovestibular symptoms in young, neurologically nor-
mal subjects, especially when spontaneous recovery occurs,
could represent an early sign of MS even when no demyeli-
nated plaques are visible in the central nervous system; it
would be recommended to evaluate these subjects with clin-
ical, radiological, and electrophysiological tests to exclude
peripheral incipient MS [129].
2.2.15. Other Autoimmune Conditions. Other autoimmune
diseases associated to audiovestibular symptoms include
Hashimoto’s thyroiditis, mixed cryoglobulinemia, giant cell
arteritis (GCA), Vogt-Koyanagi-Harada’s disease, and Ulcer-
ative Colitis.
Thyroid autoimmunity seems to affect the inner ear,
particularly inducing hearing loss at lower frequencies [131].
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In mixed cryoglobulinemia, unilateral SNHL has been
found in 22% of patients following immune complex deposit
in labyrinthine vessels determining both audiological and
vestibular symptoms [132].
Hearing loss has been reported with a prevalence rang-
ing from 7% to 100% in several case series of patients with
GCA, a multisystemic vasculitis mainly involving large-
and medium-sized blood vessels [133]. In a series of 44
patients with GCA, PTA at the time of diagnosis showed
auditory dysfunction in all patients [134]. In some patients,
hearing loss was progressive and appeared as an initial
manifestation [135].
Bilateral rapidly progressive SNHL and tinnitus and
vestibular manifestations have been observed in 48% to
62% of patients with Vogt-Koyanagi-Harada’s disease [136].
In a retrospective study, SNHL was found in about 2%
of patients with ulcerative colitis [137]. In these patients,
OAE play a central role as they may indicate a cochlear
involvement even when normal hearing thresholds are
present [138].
2.3. Audiovestibular Diagnostic Workup in Systemic
Autoimmune Diseases. The audiovestibular symptoms in
systemic autoimmune diseases are often related to the entity
of the autoimmune damage, as they may follow an inflamma-
tory process in the inner ear or a direct macrophage aggres-
sion of the inner and—mainly—outer hair cells [15].
The current literature agrees that SNHL is the most
common auditory symptom of systemic autoimmune dis-
eases [5], but due to the different presentation forms (sudden
or progressive) and severity (mild to severe) of SNHL, an
early correlation between the symptom and the systemic
autoimmune disease may be difficult. Furthermore, audio-
vestibular symptoms found in autoimmune conditions are
also common to other conditions such as diabetes and
hypertension. For these reasons, a correct differential diagno-
sis of the cause of the audiovestibular involvement is of
utmost importance.
The diagnostic process in patients presenting with a
variety of audiovestibular symptoms should begin with
individual medical history and family history followed
by traditional audiovestibular tests. The most important
audiological test battery in all cases should include PTA
possibly extended to the high-frequency region, TEOAE
and DPOAE, and ABR [5, 129]. Vestibular testing should
include a basic vestibular exam integrated with caloric test,
video head impulse test, and VEMPs [129]. The aforemen-
tioned test batteries should be performed at the onset of the
audiovestibular symptom and during follow-up to monitor
the course of the disease. Audiovestibular examination
should be integrated, when an autoimmune condition is
suspected, with specific blood tests as summarized in
Table 2 [139].
2.4. Treatment Approaches to Audiovestibular Symptoms in
Systemic Autoimmune Diseases. The treatment of audioves-
tibular symptoms should first aim at preserving the function,
such as hearing preservation and/or restoration in patients
with SNHL, and then at solving disability, distress, and
quality of life. If an underlying autoimmune disease is
suspected, treatment should be started after complete blood
exams; in fact, steroid therapy, that is, commonly used as
first-line treatment for SSNHL and other audiovestibular
symptoms, may have an effect on the underlying autoim-
mune systemic disease and delays its diagnosis.
In patients with a diagnosis of systemic autoimmune
disease, the treatment of the audiovestibular symptoms is
usually strictly related to that of the systemic condition.
Common treatment options for systemic autoimmune dis-
eases that may present an audiovestibular involvement are
summarized in Table 3.
The most common treatment for SSNHL is systemic or
intratympanic administration of high doses of corticoste-
roids, associated with hyperbaric oxygen treatment in cases
of SLE, APS, and TA [85, 86]. Other associated treatments
include antioxidant compounds to avoid progression of
SNHL [142], hearing aids to support the residual hearing
function, or cochlear implants in case of severe and pro-
found SNHL [143, 144].
Table 2: Blood tests commonly used in patients with
audiovestibular symptoms suggestive for a systemic autoimmune
condition.
Test Classification
Red and white cell counts General blood test
Coagulation test (aPTT, PT) General blood test
Creatine kinase (CK) General blood test
Alanine transaminase (ALT) General blood test
Aspartate aminotransferase (AST) General blood test
Erythrocyte sedimentation rate (ESR) Inflammatory markers
C-reactive protein (CRP) Inflammatory markers
Ferritin Inflammatory markers
Enzyme-linked immunosorbent
assay (ELISA)
Immunologic analysis
Rheumatoid Factor (RF) Antibody
Anti-cyclic citrullinated peptide
antibody (CCP)
Antibody
Anti-nuclear antibody (ANA) Antibody
Anti-double-stranded DNA
(anti-dsDNA)
Antibody
Antiextractable nuclear antigen
(anti-ENA)
Antibody
Antisignal recognition particle
(anti-SRP)
Antibody
Anti-Mi2 Antibody
Antineutrophil cytoplasmic antibody
(ANCA)
Antibody
Lupus anticoagulant (LAC) Antibody
Antiphospholipid autoantibodies (aPL) Antibody
Anticardiolipin (aCL) Antibody
Complement (C3, C4, and B) Complement
Cryoglobulins Immunoglobulin
Summary of most relevant blood tests used to investigate a possible
autoimmune condition.
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Tinnitus is commonly treated with approaches aimed
to restore hearing function, with antidepressant drugs
when a psychological involvement is detected, and using
oral supplements that combine antioxidants and vasoactive
substances [145].
Vertigo can be treated with high doses of corticosteroids
[146] associated to betahistine, a strong antagonist of the
histamine H3 receptor and a weak agonist of the histamine
H1 receptor, that improves vascularization of the inner ear
[145]. Additional therapeutic approaches include metoclo-
pramide and antidepressant drugs (inhibitor of D1 receptor)
that act on central function by reducing the sensation of
vertigo, nausea, and gastrointestinal symptoms [146]. For
chronic dizziness, specific rehabilitation treatments can be
used to favor central vestibular compensation and restore
normal balance function [147].
3. Conclusion
Audiovestibular symptoms may be found in a variety of
autoimmune diseases, and diagnosis is essential to increase
the chances of restoration when specific therapy is promptly
initiated. Inner ear involvement in autoimmune diseases is
ascertained by the history, clinical findings, an immunologic
evaluation of the patient’s serum, and response to immunosup-
pressive therapies, following exclusion of other known causes.
Table 3: Common treatment for systemic autoimmune diseases with audiovestibular involvement.
Disease Treatment Reference
Systemic lupus erythematosus (SLE)
SLE without major organ manifestations: antimalarials and/or glucocorticoids;
nonsteroidal anti-inflammatory drugs may be used judiciously for limited periods
of time in patients at low risk for drug-induced complications; in nonresponsive
patients, immunosuppressive agents such as azathioprine, mycophenolate mofetil,
and methotrexate should also be considered
[38]
Cogan’s syndrome (CS)
Prednisone 1mg/kg/day for two weeks and then tapered over 3 to 6 months;
methotrexate for long-term treatment; alternative treatments are
cyclophosphamide, azathioprine, tacrolimus, and rituximab
[45]
Sarcoidosis
High dose of corticosteroids (20–40mg/daily) for 6 to 18 months; high-dose
intravenous n-methyl-prednisone with doses of up to 30mg/kg for 1–5 days has
been commonly recommended for treatment of refractory neurosarcoidosis; in
addition, methotrexate, azathioprine, and TNF-alpha antagonists
[51]
Rheumatoid arthritis (RA)
Methotrexate at disease onset (10–15mg/week) and then 20mg/week for 4–8
weeks; it is possible to use prednisolone at high dosage (40–60mg) and tapering
to 7.5mg at week 6 for a total of 12 weeks
[140]
Antiphospholipid syndrome (APS) Chronic treatment with low dose of acetylsalicylic acid [57]
Polyarteritis nodosa (PAN)
PAN without viral syndrome: prednisone 1mg/kg/day and then tapering
when remission is reached
[71]
Behcet’s disease (BD)
Steroid treatment with azathioprine; for resistant cases, azathioprine +
interferon +TNF-α antagonists
[45]
Takayasu’s arteritis (TA)
Prednisone 1mg/kg/day; additionally, it is possible to use immunosuppressants
such as methotrexate, azathioprine, mycophenolate mofetil, leflunomide,
tacrolimus, and TNF-alpha antagonists
[79]
Relapsing polychondritis (RP)
Corticosteroid treatment at high dosages; in addition, colchicine, methotrexate,
azathioprine, intravenous immunoglobulins, minocycline, and leflunomide
[93]
Wegener granulomatosis (WG)
Prednisone or equivalent 1mg/kg/day, sometimes preceded in severe cases by
intravenous methylprednisolone pulses (7.5–15mg/kg/day) for 1–3 consecutive
days; after two weeks, tapering with a decrease of 10% every two weeks for a total
of 6 months; in case of long-term treatment (>2 years), 5mg/day; is also possible
to use cyclophosphamide and rituximab for maintenance therapy
[141]
Susac syndrome (SS)
High-dosage corticosteroids; additionally, intravenous immunoglobulin, plasma
exchange azathioprine, mycophenolate mofetil, methotrexate, cytochrome
P450 enzymes, and cyclosporine A
[103]
Sjögren’s syndrome (pSS)
Cyclosporine A for local treatment of eye disease; colchicine and steroid treatment
are used; controversial use of rituximab
[110]
Myasthenia gravis (MG)
Immunosuppressant therapy; in addition, treatment with insulin,thyroid
hormones, and pyridostigmine
[120]
Multiple sclerosis (MS)
Immunomodulating therapy: T cell suppressor (alemtuzumab, daclizumab);
B-cell modulators (rituximab, ocrelizumab); unique anti-inflammatory agents
(laquinimod); hormones (estriol); 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors; vitamin D
[130]
Treatment options for systemic autoimmune conditions, along with relevant references.
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Audiovestibular symptoms could play a role in the diagnos-
tic process of autoimmune diseases as they may be an early-
onset symptom—and in some cases, the only symptom—of
an autoimmune condition. Furthermore, they may be useful
to monitor the progression of the systemic disease.
Systemic autoimmune diseases should always be consid-
ered in patients with audiovestibular symptoms such as pro-
gressive/fluctuating SNHL with no other explainable cause.
When a systemic autoimmune disease involving the inner
ear is suspected, predisposing factors must be investigated,
such as noise exposure, ototoxic treatments, previous ear
surgery, trauma, meningitis, or family history of hearing
loss. The exclusion of concomitant conditions may be
challenging, especially in the case of presbycusis- or noise-
induced hearing loss. The low prevalence of these condi-
tions, the heterogeneity of studies available in literature,
and the absence of randomized trials are the factors that
limit the knowledge of inner ear involvement in systemic
autoimmune diseases along with underestimation of the
problem and consequent undertreatment.
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